v3.20.2
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue
Expenses:        
Research and development 6,866 3,491 12,800 6,831
General and administrative 9,015 2,855 14,915 5,115
Operating Expenses 15,881 6,346 27,715 11,946
Other income (expense):        
Interest income 116 128 439 220
Foreign exchange gains/(losses) 15 2
Total other income 131 128 439 222
Net loss (15,750) (6,218) (27,276) (11,724)
Other comprehensive gain/(loss):        
Unrealized gain/(loss) on securities available-for-sale (15) 9 (15) 18
Total comprehensive loss $ (15,765) $ (6,209) $ (27,291) $ (11,706)
Basic and diluted loss per common share (in dollars per share) $ (0.21) $ (0.13) $ (0.36) $ (0.27)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (in thousands) (in shares) 76,275 46,474 76,251 43,178

Source